Status:
WITHDRAWN
Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
Lead Sponsor:
University of Alberta
Conditions:
Enuresis
Obstructive Sleep Apnea
Eligibility:
All Genders
5-17 years
Phase:
PHASE4
Brief Summary
Enuresis (E) or bedwetting is a common pediatric complaint, and recent research has discovered a link with obstructive sleep apnea (OSA). In children, OSA is often secondary to enlargement of their ad...
Detailed Description
Enuresis (E) is a common pediatric urological complaint. Up to 15% of 5-year old children and 5% of 10-year old children are affected. Despite its prevalence, E is often ineffectively managed. Current...
Eligibility Criteria
Inclusion
- Ages between 5-17
- endorse 5/6 questions on the PSQ-22. These questions include: While sleeping, does your child: Ever snore? Snore more than half the time? Always snore? Snore loudly? Have "heavy" or loud breathing? Have trouble breathing, or struggle to breath?
- desire to use the bed alarm
Exclusion
- Children \<5
- known neurological disorders resulting in neuropathic bowel or bladder disorder including, but not limited to spinal dysraphisms and spinal cord injuries.
- significant congenital bladder anomalies, such as bladder exstrophy or posterior urethral valves
- patients with craniofacial anomalies or syndromes known to be associated with obstructive sleep apnea (i.e. Trisomy 21, muccopolysaccardiosis)
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01861145
Start Date
May 1 2013
End Date
June 1 2016
Last Update
December 18 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Stollery Children's Hospital
Edmonton, Alberta, Canada, T6G 2B7
2
Synergy Respiratory Care Centre
Sherwood Park, Alberta, Canada, T8H 0N2